Harlan Waksal - Feb 16, 2022 Form 4 Insider Report for Lyra Therapeutics, Inc. (LYRA)

Role: Executive Chair, Director
Signature: /s/ Jason Cavalier, Attorney-in-Fact for Harlan Waksal, M.D.
Stock symbol: LYRA
Transactions as of: Feb 16, 2022
Transactions value $: $0
Form type: 4
Date filed: 2/18/2022, 04:09 PM
Previous filing: Nov 9, 2021
Next filing: Apr 13, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	LYRA	Stock Option	Award	$0	+520K		$0.00	520K	Feb 16, 2022	Common Stock	520K	$4.21	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On February 16, 2022, the Reporting Person was granted an option to purchase 520,000 shares of common stock. The option vests and becomes exercisable as to 173,333 shares underlying the option when the Issuer's market capitalization reaches $250,000,000; (ii) 173,333 shares underlying the option when the Issuer's market capitalization reaches $350,000,000; and (iii) 173,334 shares underlying the option when the Issuer's market capitalization reaches $500,000,000, all subject to the Reporting Person's continued service to the Issuer through each such date.

Content

On February 16, 2022, the Reporting Person was granted an option to purchase 520,000 shares of common stock. The option vests and becomes exercisable as to 173,333 shares underlying the option when the Issuer's market capitalization reaches $250,000,000; (ii) 173,333 shares underlying the option when the Issuer's market capitalization reaches $350,000,000; and (iii) 173,334 shares underlying the option when the Issuer's market capitalization reaches $500,000,000, all subject to the Reporting Person's continued service to the Issuer through each such date.